Curriculum Vitaes
Profile Information
- Affiliation
- Department of Pharmacotherapeutics and informatics, Fujita Health University School of Medicine
- Degree
- 博士(医学)(名古屋大学)
- ORCID ID
https://orcid.org/0009-0005-2667-7057- J-GLOBAL ID
- 202001000562143382
- researchmap Member ID
- R000010558
Research Areas
7Research History
6-
Apr, 2024 - Present
-
Apr, 2023 - Present
-
Apr, 2023 - Present
-
Jan, 2018 - Mar, 2023
-
May, 2016 - Aug, 2016
Awards
2-
Mar, 2011
Papers
26-
Scientific Reports, 15(1) 41783, Nov 25, 2025 Peer-reviewed
-
Neurobiology of Disease, 217 107151-107151, Oct 22, 2025 Peer-reviewed
-
Annals of Clinical and Translational Neurology, 1-12, Sep 1, 2025 Peer-reviewedABSTRACT Objective Cerebrospinal fluid (CSF) cell‐free mitochondrial DNA (cf‐mtDNA) is a potential biomarker for Parkinson's disease (PD), but its clinical relevance remains unclear. We investigated associations between CSF cf‐mtDNA levels, body composition, nutritional status, and metabolic biomarkers in PD. Methods CSF cf‐mtDNA levels, defined as the copy numbers of two regions of the mtDNA circular molecule (mt64‐ND1 and mt96‐ND5), were quantified in 44 PD patients and 43 controls using multiplex digital PCR. The mt96‐ND5/mt64‐ND1 ratio was calculated to estimate mtDNA deletion burden. Associations with clinical features, body composition, serum nutritional markers, and plasma energy metabolism‐related organic acids were examined. Generalized linear models (GLMs) were performed to adjust for confounders. Results CSF mt64‐ND1 and mt96‐ND5 levels were lower in PD patients than controls (p = 0.002, p = 0.001), while the mt96‐ND5/mt64‐ND1 ratio showed no group difference. GLM analysis identified body composition indices and serum albumin as key determinants of cf‐mtDNA levels. Subgroup analysis showed lower cf‐mtDNA levels in PD patients with preserved body composition and nutritional status. The mt96‐ND5/mt64‐ND1 ratio displayed a biphasic association with body composition and an inverse correlation with plasma 2‐ketoglutaric acid, suggesting a link to energy metabolism. Interpretation CSF cf‐mtDNA levels are reduced in PD and influenced by body composition and nutritional status, supporting their role as a metabolic biomarker. While the cf‐mtDNA deletion ratio remained unchanged, its association with body composition suggests a complex interplay between mitochondrial integrity and metabolism. These findings highlight the relevance of cf‐mtDNA in PD pathophysiology and the need for further study.
-
In Vivo, 39(5) 2872-2882, Aug 28, 2025 Peer-reviewed
-
PLOS One, 20(8) e0329378, Aug 18, 2025 Peer-reviewedLead authorCorresponding authorRecombinant tissue-type plasminogen activators (rtPA) effectively dissolve blood clots and improve symptoms in patients with acute ischemic stroke and myocardial infraction. Although rtPA are used in patients taking antiplatelets or anticoagulants to improve clinical outcomes, combination therapy may increase the risk of hemorrhagic transformation (HT) and intracerebral hemorrhage (ICH). However, few studies have investigated the risk of HT and ICH associated with these combination therapies. This study aimed to investigate the adverse-event and drug-drug interaction signals for HT and ICH under combination therapy with alteplase and various antiplatelets or anticoagulants, using the Japanese Adverse Drug Event Report database. Adverse-event signals were evaluated using the reporting odds ratio and information components, and drug-drug interaction signals were studied using the Ω shrinkage measure, additive, multiplicative, and Chi-square statistics models. We also investigated predictors of HT and ICH, time-to-onset, and outcomes in patients receiving alteplase. HT and/or ICH signals were detected in patients receiving alteplase in combination with aspirin, P2Y12 inhibitors, cilostazol, ozagrel sodium, direct oral anticoagulants, warfarin potassium, heparin group, or argatroban. Hypertension and diabetes mellitus were significant risk factors for alteplase-induced HT. Most HT and ICH events occurred within 1 day after alteplase administration, and more than 60% of affected patients were not in recovery. In conclusion, continued monitoring is required in patients receiving alteplase in combination with any of the eight types of antiplatelets or the aforementioned anticoagulants. Additionally, the occurrence of HT or ICH within 1 day post-alteplase administration should be considered in patients with hypertension or diabetes mellitus. The findings from this study may help in understanding the risk of HT and ICH induced by rtPA in patients taking antiplatelet or anticoagulant medications, as well as in promoting the appropriate use of rtPA. Further prospective observational studies and randomized controlled trials are needed to assess these finding.
Misc.
39-
Clinical Nutrition ESPEN, 63 1235-1236, Oct, 2024 Peer-reviewed
-
日本泌尿器科学会総会プログラム抄録集 (CD-ROM), 102nd ROMBUNNO.APP-184, 2014
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 121 64P-64P, 2013
-
JOURNAL OF PHARMACOLOGICAL SCIENCES, 121 181P-181P, 2013
-
J. Res. Inst. Meijo Univ., 12(12) 35-41, 2013 Peer-reviewed
-
日本薬理学会近畿部会プログラム・要旨集 (Kinki Branch Meeting. Japanese Pharmacological Society), 121st 43, 2012
-
Annual Meeting of the Japanese Society of Toxicology, 35 S190-308, May, 2010
-
Cancer Research, 70(8_Supplement) 3646-3646, Apr 15, 2010 Peer-reviewedLead authorAbstract Platinum(IV) [Pt(IV)] compounds are being developed worldwide as next-generation platinated drugs for a broad range of cancers. Since Pt(IV) compounds show relatively stable structural features, they are applicable for oral administration. The anti-cancer mechanism of Pt(IV) compounds has been proposed as that Pt(II) generated from Pt(IV) by endogenous reductants binds to DNA, resulting in the inhibition of transcription and replication of cancer cells. Here, we investigated the interaction manner between DNA, Pt(IV) and endogenous reductants such as ascorbic acid (AsA) and glutathione (GSH). cis-Diammine-tetrachloro-Pt(IV) [cis-Pt(IV)], which is a prodrug of cisplatin [cis-diammine-dichloro-platinum(II), cis-Pt(II)], was incubated with calf thymus DNA in the presence of AsA or GSH. In the presence of AsA, cis-Pt(IV) induced oxidative damage in calf thymus DNA, in which elevated amount of 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG), a biomarker for DNA oxidation, was observed. Hydroxyl radical (HO·) scavengers (ethanol and dimethylsulfoxide) suppressed the AsA-associated oxidative damage in a dose-dependent manner, whereas superoxide dismutase and catalase did not, suggesting that HO· was involved in the DNA oxidation. CD spectral change and crosslink formation in calf thymus DNA were also observed during this DNA oxidation, suggesting the cis-Pt(IV) reduction by AsA and the DNA conformational change by cis-Pt(II)-DNA binding. However, GSH did not show any 8-oxodG formation in calf thymus DNA likely due to its own HO· scavenging capability. GSH also suppressed the cis-Pt(II)-like conformational change probably by cis-Pt(II) sequestering from DNA by GSH. This GSH-cis-Pt(II) complex formation was also suggested by agarose gel electrophoresis. In order to reveal the detailed mechanisms of the complex formation, three thiol compounds (2-mercaptoethanol, 2-mercaptoacetic acid, and 2-mercaptoethylamine) were compared with regard to the reductive complex formation capabilities with cis-Pt(II). As observed in GSH-cis-Pt(IV)-DNA system, 2-mercaptoacetic acid and 2-mercaptoethylamine inhibited cis-Pt(II)-induced CD spectral change and crosslink formation in calf thymus DNA, whereas 2-mercaptoethanol did not, suggesting that thiol- and amine-/carbonyl-groups are involved in GSH-cis-Pt(II) complex formation via ligand exchange between these groups and Cl of cis-Pt(II). In this study, we revealed that the interaction manner of cis-Pt(IV) with endogenous reductants. In the reactions, AsA reduced Pt(IV) to Pt(II) and induced DNA-crosslink formation and DNA oxidation, where HO· was produced; GSH scavenged the radical and interfered with the DNA-crosslink formation. These data strongly indicate the importance of the proper Pt(IV) ligands which are suitable for Pt(IV) reduction by endogenous reductants without complex formation with the generated Pt(II). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3646.
-
Annual Meeting of the Japanese Society of Toxicology, 34 S86-3015, Jun, 2009
-
Annual Meeting of the Japanese Society of Toxicology, 33 S128-143, Jun, 2008
-
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 128 63-63, 2008
-
J. Res. Inst. Meijo Univ., 7(7) 81-88, 2008 Peer-reviewed
Books and Other Publications
1Presentations
71Research Projects
9-
Apr, 2025 - Mar, 2027
-
Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists, Japan Society for the Promotion of Science, Apr, 2022 - Mar, 2026
-
研究助成, 公益財団法人 日東学術振興財団, Dec, 2023 - Dec, 2025
-
科学研究費助成事業, 日本学術振興会, Apr, 2022 - Mar, 2025
-
公益財団法人 愛知腎臓財団, Aug, 2023 - Mar, 2024